SamaCare, a medical technology startup that provides patients with an access tool for specialty treatment to reduce administrative burden, has secured $17 in series B funding to scale its drug prior authorization platform.
Founded in 2018 by Syam Palakurthy, the company provides an AI-powered cloud-based tool for submitting, tracking, and managing prior authorizations across drugs and payers.
The tool helps medical organizations ease administrative burdens and drive down operations costs.
SamaCare’s series B round was spearheaded by Questa Capital, with significant contributions from existing investors South Park Commons and Vive Collective.
The company will use the new capital to scale its patient access platform, which helps healthcare institutions save more time while ensuring patients get therapy quickly.
SamaCare Platform
SamaCare’s platform streamlines patients’ access to the therapies they need by digitizing the prior authorization process, which is largely paper and fax-reliant. This reduces the administrative burdens that impact healthcare delivery and patient outcomes.
It can also help remove unnecessary patient treatment delays, easing unnecessary burdens for patients, providers, health plans, and other healthcare stakeholders.
With the new financing, the company plans to develop a comprehensive and robust Script-to-Therapy Operating System to boost the platform’s capabilities in serving care providers, patients, and the pharmaceutical industry.
SamaCare is also looking to expand its offering beyond prior authorizations to create an all-in-one connected post-prescription feature that would allow for a seamless experience.
